Category Archives: Herbal

EMA make a call for scientific data for use in assessment of Ginko biloba L., folium

The herbal medicinal product committee of the DMA invite all interested parties such as pharmaceutical industry Association, healthcare professional groups, learned societies consumers and patients associations to submit any scientific data that they feel will be relevant to the assessment of  Ginko biloba L., folium as part of the establishment of community herbal monograph.

EMA Publishes Public Statement on Allium Cepa L., bulbus

EMA Publishes Public Statement on Allium Cepa L., bulbus

Full Text Here

The HMPC/MLWP decided to prepare a Community herbal monograph on Allium cepa L., bulbus as announced in the meeting report from the January 2010 HMPC meeting.
After reviewing information on the products containing Allium cepa L., bulbus and preparations thereof marketed in the Community, it appears that very few products (single-ingredient and combination) are available.
A comprehensive literature search was conducted and available data, including information on products on the market in the Community, are assessed vis-à-vis the requirements laid down in Directive 2001/83/EC and its Annex I, in particular Article 1, Article 10a and Chapter 2a.
The HMPC/MLWP concluded that the following requirements for the establishment of a Community herbal monograph on traditional and well-established herbal medicinal products containing Allium cepa L., bulbus are not fulfilled:
- the requirement laid down in Article 10a of Directive 2001/83/EC that the active substance has a recognised efficacy and an acceptable level of safety and that the period of well-established medicinal use has elapsed
- the requirement laid down in Article 16a(1)(d) of Directive 2001/83/EC that “the period of traditional use as laid down on Article 16c(1)(c) has elapsed”

Based on the above-mentioned information, the HMPC is of the opinion that a Community herbal monograph on Allium cepa L., bulbus cannot be established.
To read more about the assessment carried out, a link is provided to the page where to access the draft assessment report on Allium cepa L., bulbus and its list of references.



For Assistance with Registering Herbal Products in the EU Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publishes Herbal Monograph for Glycyrrhiza glabra L.,

EMA Publishes Herbal Monograph for Glycyrrhiza glabra L.,

Full Text Here

With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch, radix (liquorice root)
i) Herbal substance Not applicable.
ii) Herbal preparations

a) Comminuted herbal substance

b) Soft extract (DER 1:0.4-0.5), extraction solvent water

c) Soft extract (DER 3:1), extraction solvent water

Comminuted herbal substance as a herbal tea for oral use.
Herbal preparations in liquid dosage forms for oral use.
The pharmaceutical form should be described by the European Pharmacopoeia full standard term.


For Assistance with Registering Herbal Products in Europe Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publishes Comments Received on Herbal Monograph, Symphytum Officinale L., radix

EMA Publishes Comments Received on Herbal Monograph, Symphytum Officinale L., radix

Full Text Here

With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
Symphytum officinale L., radix (comfrey root)
i) Herbal substance Not applicable.
ii) Herbal preparations Liquid extract (DER 2:1), extraction solvent ethanol 65% V/V.

Herbal preparations in semi-solid dosage forms for cutaneous use.
The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

Traditional herbal medicinal product used for the symptomatic treatment of minor sprains and bruises.
The product is a traditional herbal medicinal product for use in the specified indication



For Assistance with Registering Herbal Products in the EU Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publish Community Herbal Monograph on Fraxinus Excelsior L

EMA Publish Community Herbal Monograph on Fraxinus Excelsior L

Full Text Here

With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
Fraxinus excelsior L. and Fraxinus angustifolia Vahl, folium (ash leaf)
i) Herbal substance
Not applicable.
ii) Herbal preparations
Comminuted herbal substance

Comminuted herbal substance as herbal tea (decoction or infusion) for oral use. The pharmaceutical form should be described by the European Pharmacopoeia full standard term.



For Assistance with Registration of Herbal Products Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publish Guidance on the Qualification of Low Hippocampal Volume (atrophy) by MRI

EMA Publish Guidance on the Qualification of Low Hippocampal Volume (atrophy) by MRI

Full Text Here

The European Medicines Agency’s (EMA) qualification process is a new, voluntary, scientific pathway leading to either a CHMP opinion or a Scientific Advice of novel methodologies on innovative methods or drug development tools. It includes qualification of biomarkers developed by consortia, networks, public/private partnerships, learned societies or pharmaceutical industry for a specific intended use in pharmaceutical research and development.
The Qualification team was: Prof. Fernando de Andrés Trelles (coordinator), Prof. Luca Pani (CHMP member), Dr Bertil Jonsson. The EMA Scientific Administrator for the procedure was Dr Maria Isaac.
On 23 March 2011 the Applicant C-Path CAMD Biomarker Working Group requested qualification advice for the Candidate Biomarkers of Alzheimer’s Disease (AD).
The procedure started during the SAWP meeting held on 26 – 28 April 2011.
The discussion meeting with the Applicant took place on 29 June 2011.
During its meeting held on 30 August – 01 September 2011, the SAWP agreed on the advice to be given to the Applicant. During its meeting held on 19 – 22 September 2011, the CHMP adopted the advice to be given to the Applicant. This advice is annexed to this letter.
The response given by CHMP is based on the questions and supporting documentation submitted by the Applicant, considered in the light of the current state-of-the-art in the relevant scientific fields.
The present opinion addresses the question as to whether the use of baseline measurement of low hippocampal volume (atrophy) by MRI are qualified in selecting (i.e. to categorize) subjects for trials in early Alzheimer’s Disease (AD) as having a high probability of being in the prodromal stage of the disease as defined by the Dubois Criteria (2007).
The vast majority of the data used in CHMP’s evaluation have been submitted by CAMD, the applicant that requested the qualification, and are all published literature available in the public domain. They have been supplemented by further information searched required by members of the qualification team.


For Assistance with Regulation of Herbal products in Europe Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publish List of References used in Assessment of Viola; Arvensis Murray, Vulgaris Koch

EMA Publish List of References used in Assessment of Viola; Arvensis Murray, Vulgaris Koch

Full Text Here

The Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.
Allen DE, Hatfield G. Medicinal plants in folk tradition. Timber Press, Portland, Cambridge 2004, 111-112
Amenta R, Camarda L, Di Stefano V, Lentini F, Venza F. Traditional medicine as a source of new therapeutic agents against psoriasis. Fitoterapia 2000, 71:13-120
Bandyukova VA, Sergeeva N. Rutin in some cultivated plants. Khimia Prirododnich Soedinieni 1974, 4:524
Baszyński T. Zawartość tokoferoli (witaminy E) w kwiatach roślin łąkowych. Roczniki Nauk Rolniczych 1961, 74:757-762
Behmanesh Y, Abdollahi M. Haemolysis after consumption of Viola tricolor. WHO Drug Information 2002, 16:15-16
Bobowska M, Gobiec K, Grzęda W, Kempisty J, Sadowski Z. Poradnik Terapeutyczny. PZWL, Warszawa 1975, 408-409
Boruch T, Góra J, Bielawska M, Świątek L, Łuczak S. Extract of plants and their cosmetic application. Part XI. Extract from herb of Viola tricolor. Pollena: TSPK 1985, 82:38-40
Bradley PR. editor.Heartsease. Violae tricoloris herba. British Herbal Compendium. Vol 2. British Herbal Medicine Association, Bornemouth 2006, 207-210
Braun H. Heilpflanzen-Lexikon fűr Ärzte und Apotheker. Viola tricolor. Feldstiefmütterchen. Gustav Fischer Verlag, Stuttgart 1974, 197
Brinker F. Herb contraindications and drug interactions. Appendix A. Herbs to be used with caution. Eclectic Medical Publications 2001, 209-211….


For Assistance with Regulation of Herbal Products in Europe and the USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publish Assessment Report on Viola Tricolor L.

EMA Publish Assessment Report on Viola Tricolor L.

Full Text Here

The herbal substance of wild pansy and/or European field pansy is mentioned in several well known handbooks such as Madaus (1938), Martindale (2007), Wichtl (1994; 2004), PDR for Herbal Medicines (2000; 2004), German Commission E Monograph, European Pharmacopoeia 6.0, Duke’s Handbook of Medicinal Herbs (2002), Hänsel et al. (1994) and Chevallier Encyclopedia of Medicinal Plants (1996).
In the European Pharmacopoeia it is described as the dried flowering aerial parts of Viola tricolor L. (wild pansy) and/or spp. Viola arvensis Murray (Gaud.) and Koch (Oborny) (European field pansy). Wild pansy must contain at least 1.5 percent of flavonoids, calculated with reference to the dried substance, expressed as violanthin.
Wild pansy belongs to the family of Violaceae. The herb is distributed in Europe and Asia. Flowering aerial parts of wild pansy are harvested during summer.



For Assistance with The Regulation of Herbal Products in Europe or the USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publish Procedure on Publication of HMPC Statements with Community Herbal Monographs are not Established

EMA Publish Procedure on Publication of HMPC Statements with Community Herbal Monographs are not Established.

Full Text Here

This procedure has been prepared to clarify the conditions when the Committee on Herbal Medicinal Products (HMPC) shall establish a public statement on an herbal substance which was on the HMPC priority list, in the situation where it does not establish a Community herbal monograph on that herbal substance and preparations thereof.
The publication of this procedure is part of the European Medicines Agency’s initiatives to improve transparency in the regulatory and scientific processes followed by the HMPC in fulfilling its tasks as defined by the European legislation.

This procedure does not address the situations where:
a Community list entry cannot be established
a herbal preparation is not included in a Community herbal monograph
The justification as to why a Community list entry cannot be established together with the relevant Community herbal monograph can be found in the assessment report (AR). For the assessment works carried out so far which had led to the publication of final monographs, the absence of adequate genotoxicity data, as part of the evidence required to demonstrate a safe use, has been the primary justification to the non-establishment of a Community list entry on a herbal substance and/or preparations thereof.
The justification as to why a given herbal preparation is not included in a monograph can be found in the AR and/or in the ‘Overview of comments received during the public consultation’. It cannot be expected that such a justification is available for every possible preparation. Current practice is that justification is provided for preparations which can be found on the market of one or several Member States of the European Union and made known to the Rapporteur either by members of the HMPC/Working Party on Community Monographs and Community List (MLWP) or by interested parties via their comments on draft monographs.



For Assistance with Herbal Product Registration in the UK, EU and USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publish Procedure for Calls for Scientific Data for Use in HMPC Assessment Work

EMA Publish Procedure for Calls for Scientific Data for Use in HMPC Assessment Work

Full Text Here

In accordance with Directive 2001/83/EC amended as regards traditional herbal medicinal products through Directive 2004/24/EC (1), it is the task of the Committee on Herbal Medicinal Products (HMPC) to establish a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (Article 16f). Furthermore, the HMPC shall establish Community herbal monographs for herbal medicinal products (Article 16h(3)). The HMPC has also undertaken to ensure that monographs and list entries remain up-to-date (scientific state of the art) by assessing regularly the need for their revision (5, 6).
The legislation does not specify how scientific data relating to the assessment work for the monographs and list entries should be identified and compiled. The HMPC discussed a number of possibilities and agreed on a practice subject to 3 conditions:
1. The compilation of data will be a public procedure; and
2. The compilation will take place within a framework of criteria to be predefined by the HMPC (e.g. in relation to literature search strategy); and
3. The compilation shall seek to ensure that a complete set of bibliographic references and/or scientific data will be available to the Rapporteur(s).

No requirements for scientific standards are provided in the legislation and submission by interested parties of bibliographic references and/or scientific data is voluntary. However, some guidance as to the scope of data requested can be provided through the application of Directive 2001/83/EC:
Bibliographic data submitted in relation to well-established medicinal use should provide evidence that the constituent or the constituents of the medicinal product has or have a well-established medicinal use with recognised efficacy and an acceptable level of safety within the meaning of Directive 2001/83/EC as amended (Recital 2 of Directive 2004/24/EC).
Bibliographic data submitted in relation to traditional-use should provide evidence that the medicinal product in question, or a corresponding product has been in medicinal use throughout a period of at least 30 years preceding the date of the application, including at least 15 years within the Community (Article 16c(1)(c)).
In addition, the contributor is expected to submit both favorable and unfavorable data as well as to ensure that the newest publications are taken into account.
Further guidance on the requirements can be found in the HMPC ‘Guideline on non-clinical documentation for herbal medicinal products in applications for marketing authorisation (bibliographical and mixed applications) and in applications for simplified registration’ (2) and the HMPC ‘Guideline on the assessment of clinical safety and efficacy in the preparation of Community herbal monographs for well-established and of Community herbal monographs/entries to the Community list for traditional herbal medicinal products/substances/preparations’ (3).


For Assistance with Registering a Herbal Product in the EU or UK Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publishes Procedures on the Systematic Review of Community Herbal Monographs and Supporting Documents

EMA Publishes Procedures on the Systematic Review of Community Herbal Monographs and Supporting Documents

Full Text Here

The systematic review (assessment of the need for revision) by the Committee on Herbal Medicinal Products (HMPC) of its Community herbal monographs is laid down in section 3.2 of the ‘Reflection paper on the reasons and timelines for revision of final Community herbal monographs and Community list entries’ (EMA/HMPC/326440/2007). The need for a revision will be considered every 5 years in order to ensure that Community herbal monographs remain up-to-date (scientific state of the art).
This procedure addresses the scope, timelines and documenting aspects of the review and possible subsequent revision. The purpose of this document is to enable a consistent process for all monographs adopted by the HMPC.
The same procedure applies to Community list entries as implied in Article 16f(3) of Directive 2004/24/EC. The revision of Community list entries will take place in parallel to or shortly after the revision of related monographs. When a Community list entry is revised, the Comitology procedure will be followed at the European Commission level after transmission by the EMA.



For Assistance with Registering a Herbal Product in the EU and UK Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publishes Guidance on Companies Seeking Scientific advice on Traditional Herbal Medicinal Products

EMA Publishes Guidance on Companies Seeking Scientific advice on Traditional Herbal Medicinal Products

Full Text Here

The HMPC adopts its scientific recommendations on the medicinal uses of herbal substances and herbal preparations (laid down in Community herbal monographs) by either consensus or a majority vote. The members of the HMPC (chosen for their role and experience in the evaluation of herbal medicinal products and representing the national competent authorities) express their divergent position when they do not support the entire content of a monograph. The divergent positions are published on the Agency website, as an appendix to the HMPC opinion. These positions may be valuable information for companies as to the specific approaches taken by some regulatory authorities on a national level. The names of the members who expressed the divergent positions can be obtained upon submission of a request for access to documents according to the ‘EMA Policy on access to documents (related to medicinal products for human and veterinary use).

Note: It should be noted that this document has been produced for guidance only and should be read in conjunction with the relevant legislation and guidance, including:
Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004
Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use.
Regulation (EC) No 1905/2005 of the European Parliament and of the Council of 14 November 2005 amending Regulation (EC) No 297/95 on fees payable to the European Medicines Agency
Rules for the implementation of Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency and other measures (EMA/MB/818152/2009)
HMPC rules of procedures (EMA/HMPC/139800/2004 Rev.2)
EMA policy on the appropriate coordination between the scientific committees of the Agency (Policy 0009, EMA/124704/2005 Rev.1)



For Assistance with Registering a Herbal Product in the UK, USA or EU Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publish Guidance on Systematic Review of Community Herbal Monograph Supporting Documents

EMA Publish Guidance on Systematic Review of Community Herbal Monograph Supporting Documents

Full Text Here

The systematic review (assessment of the need for revision) by the Committee on Herbal Medicinal Products (HMPC) of its Community herbal monographs is laid down in section 3.2 of the ‘Reflection paper on the reasons and timelines for revision of final Community herbal monographs and Community list entries’ (EMA/HMPC/326440/2007). The need for a revision will be considered every 5 years in order to ensure that Community herbal monographs remain up-to-date (scientific state of the art).
This procedure addresses the scope, timelines and documenting aspects of the review and possible subsequent revision. The purpose of this document is to enable a consistent process for all monographs adopted by the HMPC.
The same procedure applies to Community list entries as implied in Article 16f(3) of Directive 2004/24/EC. The revision of Community list entries will take place in parallel to or shortly after the revision of related monographs. When a Community list entry is revised, the Comitology procedure will be followed at the European Commission level after transmission by the EMA.



For Assistance with Registration of Herbal products in the EU, UK or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publish List of references supporting the assessment of Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix

EMA Publish List of references supporting the assessment of Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix

Full Text Here

The Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.
Agbabiaka TB, Guo R, Ernst E. Pelargonium sidoides for acute bronchitis: A systemic review and meta-analysis. Phytomedicine 2008, 15:378-385.
Bachert C, Schapowal A, Funk P, Kieser M. Treatment of acute rhinosinusitis with the preparation from Pelargonium sidoides EPs® 7630: a randomized, double-blind, placebo-controlled trial. Rhinology 2009, 47:51-58.
Beil W, Kilian P. EPs® 7630, an extract from Pelargonium sidoides roots inhibits adherence of Helicobacter pylori to gastric epithelial cells. Phytomedicine 2007, 14:5-8.
Bereznoy VV, Riley DS, Wassmer G, Heger M. Efficacy of extract of Pelargonium sidoides in children with acute non-group A beta-haemolytic streptococcus tonsillophyaryngitis: a randomized, double-blind, placebo-controlled trial. Altern Ther Health Med 2003, 9:68-78.
Bladt S, Wagner H. “Umckaloabo”-Droge der afrikanischen Volksmedizin. Dtsh Apoth Ztg 1977, 117:1655-1660.
Bladt S, Wagner H. Cumarindrogen: Qualitatsprüfung der Umcka-Droge und ihrer Zubereitungen. Dtsh Apoth Ztg 1988, 128:292-296.
Bladt S, Wagner H. From the Zulu medicine to the European phytomedicine Umckaloabo®. Phytomedicine 2007, 14:2-4.
Blochin B, Haidvogl M, Heger M. Umckaloabo im Vergleich zu Acetylcystein bei Kindern mit acuter Bronchitis: prospective, randomisierte, kontrollierte, offene Studie zur Wirksamkeit und Vertraglichkeit. Der Kassenarzt 1999, 49:46-50.
Brendler T, van Wyk BE. A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae). J Ethnopharmacol 2008, 119:420-433….



For Assistance with Registering a Product in the UK, EU or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publish Assessment report on Olea europaea L., folium

EMA Publish Assessment report on Olea europaea L., folium

Full Text Here

Herbal substance(s) (binomial scientific name of the plant, including plant part)
Olea europaea L. folium (olive leaf)
Herbal preparation(s)
Herbal substance
Fresh or dried leaves
Herbal preparations
Comminuted dried leaves for herbal tea
Pharmaceutical forms
Herbal substance and comminuted herbal substance as herbal tea for oral use.


For Assistance with Registering Herbal Products in the UK, EU or the USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publishes Assessment report on Tanacetum parthenium (L.) Schulz Bip., herba

EMA Publishes Assessment report on Tanacetum parthenium (L.) Schulz Bip., herba

Full Text Here

Herbal substance(s) (binomial scientific name of the plant, including plant part)
Tanacetum parthenium (L.) Schulz Bip., herba
Herbal preparation(s) Powdered herbal substance
Pharmaceutical forms Herbal preparation in solid dosage forms for oral use.
Rapporteur Prof Gioacchino Calapai
Assessors Prof Gioacchino Calapai/Marisa Delbò



For Assistance with Registering a Herbal Product in the UK, EU or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publish List of references supporting the assessment of Oenothera biennis L.; Oenothera lamarckiana L., oleum

EMA Publish List of references supporting the assessment of Oenothera biennis L.; Oenothera lamarckiana L., oleum

Full Text Here

The Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.
Abou El-Ela SH, Prasse KW, Carroll R, et al. Effects of dietary primrose oil on mammary tumorigenesis induced by 7,12-dimethylbenz(a)anthracene. Lipids 1987; 22(12): 1041-1044
Abou El-Ela SH, Prasse KW, Carroll R, et al. Eicosanoid synthesis in 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in sprague-dawley rats fed primrose oil, menhaden oil or corn oil diet. Lipids 1988; 23(10): 948-954
Aman MG, Mitchell EA, Turbott SH. The effects of essential fatty acid supplementation by Efamol in hyperactive children. J Abnorm Child Psychol 1987; 15(1): 75-90
Al-Shabanah OA. Effect of evening primrose oil on gastric ulceration and secretion induced by various ulcerogenic and necrotizing agents in rats. Food Chem Toxicol 1997; 35(8): 769-775
Anonymous. Surgical research society abstracts. Br J Surg 1981; 68: 801-824
Anstey A, Quigley M, Wilkinson JD. Topical evening primrose oil as treatment for atopic eczema. J Dermatol Treat 1990; 1: 199-201
Bamford JTM, Gibson RW, Renier CM. Atopic eczema unresponsive to evening primrose oil (linoleic and -linolenic acids). J Am Acad Dermatol 1985; 13(6): 959-965
Barnes J, Anderson LA, Phillipson JD. Herbal Medicines. Pharmaceutical Press, London 2007, 251-255
Bédard M. Evening primrose oil – still promising, but unproven. Can Pharm J 2003; 136(10): 41-42
Belch JJF, Shaw B, O’Dowd A, et al. Evening primrose oil (Efamol) as a treatment for cold-induced vasospasm (Raynauds phenomenon). Prog Lipid Res 1986; 25: 335-340


For Assistance with Regulating Herbal Products in the UK, EU and USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publish List of references supporting the assessment of Tanacetum parthenium (L.) Schulz Bip., herba

EMA Publish List of references supporting the assessment of Tanacetum parthenium (L.) Schulz Bip., herba

Full Text Here

The Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.
Anderson D, Jenkinson PC, Dewdney RS, Blowers SD, Johnson ES, Kadam NP. Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: a comparison of chronic feverfew users and matched non-users. Hum Toxicol 1988, 7:145-152.
Anderson KN, Bejcek BE. Parthenolide induces apoptosis in glioblastomas without affecting NF-kappaB. J Pharmacol Sci 2008, 106:318-320.
Awang DVC. Prescribing therapeutic feverfew (Tanacetum parthenium (L.) Schultz bip., syn. Chrysanthemum parthenium (L.) Bernh.). Elsevier Science Inc 1998, 1(1):11-13.
Bamford CC, Tepper SJ. Daily pharmacologic prophylaxis of episodic migraine. Tech Reg Anesth Pain Manag 2009, 13:20-27.
Barnes J, Anderson LA, Philipson JD. Herbal Medicines. 3rd ed. Pharmaceutical Press, London 2007.
Barsby RW, Knight DW, McFadzean I. A chloroform extract of the herb feverfew blocks voltage-dependent potassium currents recorded from single smooth muscle cells. J Pharm Pharmacol 1993, 45:641-645.
Barsby RW, Salan U, Knight DW, Hoult JR. Feverfew extracts and parthenolide irreversibly inhibit vascular responses of the rabbit aorta. J Pharm Pharmacol 1992, 44:737-740.
Bejar E. Parthenolide inhibits the contractile responses of rat stomach fundus to fenfluramine and dextroamphetamine but not serotonin. J Ethnopharmacol 1996, 50:1-12.
British Herbal Pharmacopoeia. British Herbal Medicine Association, Bournemouth 1990.
British Herbal Pharmacopoeia. 4th ed. British Herbal Medical Association, London 1996…….



For Assistance with Registering a Herbal Product in the UK, EU or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publish Assessment report on Arctostaphylos uva-ursi (L.) Spreng., folium

EMA Publish Assessment report on Arctostaphylos uva-ursi (L.) Spreng., folium

Full Text Here

Herbal substance(s) (binomial scientific name of the plant, including plant part)
Arctostaphylos uva-ursi (L.) Spreng., folium (bearberry leaf)
Herbal preparation(s)
A) Comminuted herbal substance
B) Powdered herbal substance
C) Dry extract (DER 3.5 – 5.5:1), extraction solvent ethanol 60% (V/V) containing 23.5 – 29.3% of hydroquinone derivatives calculated as anhydrous arbutin (spectrophotometry)
D) Dry extract (DER 2.5 – 4.5:1), extraction solvent water containing 20 – 28% of hydroquinone derivatives calculated as anhydrous arbutin (spectrophotometry)
Pharmaceutical forms
Herbal substance or herbal preparations in solid dosage forms or as herbal tea/macerate for oral use.



For Assistance with Registering Herbal Products in the EU, UK or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

EMA Publishes Overview of comments received on Community herbal monograph on Juniperus communis L., aetheroleum

EMA Publishes Overview of comments received on Community herbal monograph on Juniperus communis L., aetheroleum

Full Text Here

Organisations and/or individuals that commented on the draft Community herbal monograph> on Juniperus communis L., aetheroleum as released for public consultation on 15 March 2010 until 15 August 2010.
Organisations and/or individuals
1 European Scientific Cooperative on Phytotherapy (ESCOP)



For Assistance with Registering a Herbal Product in the UK, EU or USA Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”